{"DataElement":{"publicId":"2546165","version":"1","preferredName":"Ovarian Antiestrogen Hormone Therapy Administered Type","preferredDefinition":"a description of procedures, treatment or agents given to an individual to suppress production of female reproductive hormones (ovarian function suppression).","longName":"OFS_HORMONTX_ADM_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2013776","version":"4","preferredName":"Ovarian Antiestrogen Hormone Therapy Administered","preferredDefinition":"related to therapy given using agents which suppress production of female reproductive hormones (chemicals produced by the ovaries and circulated in the bloodstream).","longName":"OV_ANTIES_HORMTX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2546786","version":"1","preferredName":"Ovarian Antiestrogen Therapy Hormone Therapy","preferredDefinition":"Having to do with the ovaries, the female reproductive glands in which the ova (eggs) are formed. The ovaries are located in the pelvis, one on each side of the uterus.:No Value Exists:Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"C28047:C15757:C15445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian","conceptCode":"C28047","definition":"Having to do with the ovaries, the female reproductive glands in which the ova (eggs) are formed. The ovaries are located in the pelvis, one on each side of the uterus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Antiestrogen Therapy","conceptCode":"C15757","definition":"Drug treatment to block the action of the female hormone estrogen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"22DD3727-BD6E-6FF0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-22","endDate":null,"createdBy":"PWEST","dateCreated":"2006-11-22","modifiedBy":"ONEDATA","dateModified":"2006-11-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"22C8A2A9-BFEA-0B50-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"PWEST","dateCreated":"2006-11-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"updated for ISO compliance; DEC generated by Compliance Review Tool","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2546164","version":"1","preferredName":"Ovarian Antiestrogen Hormone Therapy Administered Type","preferredDefinition":"a description of procedures, treatment or agents given to an individual to suppress production of female reproductive hormones (ovarian function suppression).","longName":"OFS_HORMONTX_ADM_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"25","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"LHRH Agonist","valueDescription":"LHRH agonist","ValueMeaning":{"publicId":"2573099","version":"1","preferredName":"LHRH agonist","longName":"2573099","preferredDefinition":"A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gonadotropin-releasing Hormone Analog","conceptCode":"C1910","definition":"A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA98-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-08","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"22C93AB6-D045-089A-E044-0003BA3F9857","beginDate":"2006-11-21","endDate":null,"createdBy":"PWEST","dateCreated":"2006-11-21","modifiedBy":"ONEDATA","dateModified":"2006-11-21","deletedIndicator":"No"},{"value":"Ovarian radiation","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2559934","version":"1","preferredName":"Radiation Therapy","longName":"2559934","preferredDefinition":"use PHOTOTHERAPY, LASER THERAPY, or ULTRAVIOLET THERAPY for therapeutic radiation with visible, laser, or ultraviolet light, respectively.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B72B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"REEVESD","dateModified":"2009-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"22C93AB6-D056-089A-E044-0003BA3F9857","beginDate":"2006-11-21","endDate":null,"createdBy":"PWEST","dateCreated":"2006-11-21","modifiedBy":"ONEDATA","dateModified":"2006-11-21","deletedIndicator":"No"},{"value":"Oophorectomy","valueDescription":"Bilateral surgical oophorectomy","ValueMeaning":{"publicId":"2576596","version":"1","preferredName":"Bilateral surgical oophorectomy","longName":"2576596","preferredDefinition":"Bilateral surgical oophorectomy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F841-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-10-14","modifiedBy":"CAMPBELB","dateModified":"2005-10-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"22C93AB6-D067-089A-E044-0003BA3F9857","beginDate":"2006-11-21","endDate":null,"createdBy":"PWEST","dateCreated":"2006-11-21","modifiedBy":"ONEDATA","dateModified":"2006-11-21","deletedIndicator":"No"},{"value":"Medical suppression","valueDescription":"Medical suppression of ovarian function","ValueMeaning":{"publicId":"2646292","version":"1","preferredName":"Medical suppression of ovarian function","longName":"2646292","preferredDefinition":"Medical suppression of ovarian function","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31DB3531-E21A-526E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31D9DE2F-1C5A-527A-E044-0003BA3F9857","beginDate":"2007-06-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-01","modifiedBy":"ONEDATA","dateModified":"2007-06-01","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"31D9DE2F-1C66-527A-E044-0003BA3F9857","beginDate":"2007-06-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-01","modifiedBy":"ONEDATA","dateModified":"2007-06-01","deletedIndicator":"No"},{"value":"Bilateral oophorectomy","valueDescription":"BILATERAL OOPHORECTOMY","ValueMeaning":{"publicId":"2561143","version":"1","preferredName":"BILATERAL OOPHORECTOMY","longName":"2561143","preferredDefinition":"BILATERAL OOPHORECTOMY","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BBE4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-05-13","endDate":null,"createdBy":"CVALMONT","dateCreated":"2002-05-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"604FEE48-9CAC-B575-E040-BB89AD433315","beginDate":"2009-01-12","endDate":null,"createdBy":"CDECURATE","dateCreated":"2009-01-12","modifiedBy":"CDECURATE","dateModified":"2009-01-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"22C8A2A9-BFFB-0B50-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"PWEST","dateCreated":"2006-11-21","modifiedBy":"REEVESD","dateModified":"2009-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"},{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"}]},{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"}]}],"AlternateNames":[{"name":"caBIG","type":"USED_BY","context":"NCIP"}],"ReferenceDocuments":[{"name":"Specify type","type":"Preferred Question Text","description":"Specify type","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Ovarian Function Suppression Type","url":null,"context":"CTEP"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"22CA4705-EE1A-2566-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"PWEST","dateCreated":"2006-11-21","modifiedBy":"REEVESD","dateModified":"2011-03-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}